23G玻璃体切割术前、术中辅助玻璃体内注射康柏西普治疗增生型糖尿病视网膜病变(PDR)的疗效分析

目的 对比分析23G玻璃体切割术前、术中辅助玻璃体内注射康柏西普对增生型糖尿病视网膜病变(proliferative diabetic retinopathy,PDR)疗效及手术相关并发症的影响.方法 回顾性分析南昌大学第二附属医院2015年1月至2016年2月收治的PDR患者42例(42眼)的资料,其中22例在行23G玻璃体切割术前1周于玻璃体内注射康柏西普0.05 mL(A组);另外20例在行23G玻璃体切割术完毕时于玻璃体内注射康柏西普0.05 mL(B组).观察两组患眼手术时间,术后玻璃体内出血情况,术中、术后其他指标及最佳矫正视力等的差异.结果 A组手术完成时间、电凝止血率、医源性裂孔发生率及术中出血率均低于B组.两组术后6个月视力比较差异无统计学意义(P＞0.05),但两组术前、术后视力相比差异均有统计学意义(均为P ＜0.05).术后早期玻璃体出血(≤1个月);A组有4眼(18.2％),B组有3眼(15.0％),两组相比差异无统计学意义(P＞0.05).术后晚期玻璃体出血(＞1个月);A组6眼(27.3％),B组未发现玻璃体内出血,两组相比差异有统计学意义(P＜0.05).随访期间A组有3眼因术后玻璃体再出血,需再次手术,再次手术率13.6％;B组有2眼术后发生牵拉性视网膜脱离,需再次手术治疗,再次手术率10.0％.视网膜激光光凝补充治疗:A组需(2.3±1.0)次,B组需(1.4±0.6)次,两组比较差异有统计学意义(P＜0.05).结论 23G玻璃体切割术中联合康柏西普治疗PDR可有效预防术后早晚期出血,为术后激光补充治疗提供有利条件,减少激光补充治疗次数;而术前联合康柏西普治疗PDR可缩短手术时间,减少术中并发症发生,降低术后早期出血率.

Preoperative and intraoperative adjunctive intravitreal conbercept in 23G vitrectomy for proliferative diabetic retinopathy

Objective To discuss the effects and influence of preoperative and postoperative adjunctive intravitreal conbercept in 23G vitrectomy for proliferative diabetic retinopathy (PDR).Methods A retrospective research was performed on 42 PDR eyes from January 2015 to February 2016 in the Second Affiliated Hospital of Nanchang University,who received either intravitreal 0.05 mL conbercept injection 7 days before 23G vitrectomy (group A,n =22) or intravitreal 0.05 mL conbercept injection at the end of 23 G vitrectomy (group B,n =20).The operative time,postoperative vitreous hemorrhage (VH),intraoperative and postoperative other differences of clinical indicators and postoperative best-corrected visual acuity (BCVA) between the two groups were compared.Results The average operation time,intraoperative electric coagulation hemostasis rate,iatrogenic hiatal incidence and intraoperative hemorrhage rate of group A were lower than those of group B (all P ＜ 0.05).BCVA at 6 months after surgery did not differ significantly between two groups (P ＞ 0.05),but the difference was statistically significant between pre-operation and post-operation (P ＜ 0.05).The incidences of early (≤ 1 month) postoperative VH were 18.2％ (4 eyes) and 15.0％ (3 eyes) in group A and B,respectively (P ＞ 0.05).The incidences of later (＞ 1 month) postoperative VH were 27.3％ (6 eyes) and 0 in group A and B,respectively,the difference was statistically significant (P ＜0.05).The percentages of reoperation were 13.6％ (3eyes with postoperative VH) and 10.0％ (2 eyes with traction retinal detachment) respectively in group A and B.The average times of supplementary laser photocoagulation were (2.3 ± 1.0) times and (1.4 ±0.6) times in group A and B,respectively in follow-up period (P ＜ 0.05).Conclusion The adjunctive use of intraoperative intravitreal injection of conbercept can prevent effectively postoperative VH and decrease conveniently the time of supplementary laser photocoagulation in 23G vitrectomy for PDR,as well as the preoperative adjunctive use can decrease the operation time,intraoperative complications and incidences of early postoperative VH.